SPRO - Spero Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue1,979335-
Cost of Revenue32,86926,33311,125
Gross Profit-30,890-25,998-11,125
Operating Expenses
Research Development---
Selling General and Administrative10,8407,2232,202
Non Recurring---
Total Operating Expenses43,70933,55613,327
Operating Income or Loss-41,730-33,221-13,327
Income from Continuing Operations
Total Other Income/Expenses Net1,844580174
Earnings Before Interest and Taxes-41,730-33,221-13,327
Interest Expense---
Income Before Tax-39,886-32,641-13,153
Income Tax Expense---
Minority Interest355-3,808-453
Net Income From Continuing Ops-39,886-32,641-13,153
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-38,743-25,491-10,154
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-46,097-29,928-13,427